Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Bought by Federated Hermes Inc.

Federated Hermes Inc. raised its holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 63.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,105,779 shares of the biopharmaceutical company's stock after purchasing an additional 430,432 shares during the quarter. Federated Hermes Inc. owned 1.81% of Sage Therapeutics worth $6,004,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in SAGE. US Bancorp DE lifted its holdings in shares of Sage Therapeutics by 22.3% in the 4th quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company's stock valued at $67,000 after buying an additional 2,268 shares during the period. Teacher Retirement System of Texas raised its position in Sage Therapeutics by 21.6% in the fourth quarter. Teacher Retirement System of Texas now owns 13,768 shares of the biopharmaceutical company's stock worth $75,000 after acquiring an additional 2,446 shares in the last quarter. Picton Mahoney Asset Management lifted its holdings in Sage Therapeutics by 126.0% in the fourth quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company's stock valued at $35,000 after acquiring an additional 3,581 shares during the period. Geode Capital Management LLC boosted its position in shares of Sage Therapeutics by 0.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,242,854 shares of the biopharmaceutical company's stock worth $8,975,000 after purchasing an additional 3,757 shares in the last quarter. Finally, Wells Fargo & Company MN grew its stake in shares of Sage Therapeutics by 27.3% during the 4th quarter. Wells Fargo & Company MN now owns 33,051 shares of the biopharmaceutical company's stock worth $179,000 after purchasing an additional 7,087 shares during the period. Institutional investors and hedge funds own 99.22% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

SAGE has been the subject of several recent analyst reports. Bank of America initiated coverage on shares of Sage Therapeutics in a research note on Tuesday, March 11th. They issued an "underperform" rating and a $5.00 price objective for the company. HC Wainwright reiterated a "neutral" rating and set a $12.00 price target (down from $14.00) on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Stifel Nicolaus decreased their price target on Sage Therapeutics from $10.00 to $6.00 and set a "hold" rating on the stock in a research note on Monday, December 16th. Wedbush reaffirmed a "neutral" rating and issued a $6.00 price objective on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Finally, Piper Sandler decreased their target price on Sage Therapeutics from $26.00 to $9.00 and set an "overweight" rating on the stock in a research report on Thursday, January 2nd. Three investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $8.81.

Sage Therapeutics Stock Performance

SAGE stock traded up $0.14 during trading on Tuesday, hitting $7.54. The stock had a trading volume of 845,732 shares, compared to its average volume of 1,250,199. The stock has a market cap of $463.57 million, a price-to-earnings ratio of -1.14 and a beta of 0.48. The company's 50 day moving average price is $7.45 and its two-hundred day moving average price is $6.71. Sage Therapeutics, Inc. has a 1-year low of $4.62 and a 1-year high of $15.74.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%. As a group, sell-side analysts forecast that Sage Therapeutics, Inc. will post -3.52 earnings per share for the current fiscal year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.